PARTNERING
BUSINESS DEVELOPMENT
Out-licensing / Partnering
Following Amarin’s respositioning to focus on its cardiovascular disease programs, the following CNS programs are now available for partnering:
- EU rights to AMR101 for Huntington’s Disease (MAA accepted for review by EMEA)
- Global rights to EN101 for myasthenia gravis
- Global rights to sublingual apomorphine for advanced Parkinson's disease
- Global rights to nasal lorazepam for emergency seizures in epilepsy
- Global rights to AMR103 for Parkinson's disease
Please contact Stuart Sedlack or David Boal at bd@amarincorp.com for more information
